Spain provides targeted therapy for various cancers, including non-small cell lung cancer, prostate, breast, melanoma, and neuroendocrine tumors. Specialized centers in Barcelona and Madrid use precision oncology to target specific genetic mutations like ALK, KRAS, BRAF, and EGFR within JCI-accredited facilities.
- Lung cancer: Treatment covers genomic alterations in genes like ALK, RET, ROS1, and EGFR.
- Prostate cancer: Advanced cases utilize Lutetium-177 therapy at specialized nuclear medicine departments.
- Breast cancer: Precision protocols target HER2+ and triple-negative types through molecular research.
- Pediatric oncology: SJD Barcelona Children’s Hospital develops molecular therapies for neuroblastoma and sarcomas.
Bookimed Expert Insight: While many countries focus on generic targeted protocols, Spanish centers like Clinica Universidad de Navarra specialize in rare sarcomas. Their 74% cure rate for sarcoma stems from combining targeted approaches with limb-preservation surgery. This level of specialization draws international patients seeking alternatives to standard amputation or broad-spectrum chemotherapy.
Patient Consensus: Patients emphasize the importance of genetic testing before traveling, as therapy response depends entirely on specific mutations like KRAS or BRAF. Many note that advanced therapies, such as engineered T-cells, have provided complete remission even when other treatments failed.